Blue Owl Capital Holdings LP Acquires 200,000 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA)

Blue Owl Capital Holdings LP grew its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) by 5.1% during the second quarter, Holdings Channel.com reports. The institutional investor owned 4,091,118 shares of the company’s stock after purchasing an additional 200,000 shares during the quarter. Ikena Oncology accounts for approximately 1.9% of Blue Owl Capital Holdings LP’s investment portfolio, making the stock its 17th biggest holding. Blue Owl Capital Holdings LP owned 0.08% of Ikena Oncology worth $6,750,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of IKNA. Vestal Point Capital LP bought a new position in shares of Ikena Oncology during the 4th quarter worth approximately $636,000. BVF Inc. IL raised its position in shares of Ikena Oncology by 50.5% during the fourth quarter. BVF Inc. IL now owns 4,769,164 shares of the company’s stock worth $9,395,000 after purchasing an additional 1,600,000 shares during the period. Marquette Asset Management LLC acquired a new position in shares of Ikena Oncology during the first quarter worth approximately $104,000. Acadian Asset Management LLC raised its position in shares of Ikena Oncology by 1,201.8% during the first quarter. Acadian Asset Management LLC now owns 282,782 shares of the company’s stock worth $400,000 after purchasing an additional 261,060 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Ikena Oncology by 813.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock worth $729,000 after purchasing an additional 457,245 shares during the period. 75.00% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of Ikena Oncology in a research report on Monday, August 12th.

Ikena Oncology Trading Up 0.6 %

NASDAQ IKNA opened at $1.73 on Friday. The firm has a market capitalization of $83.49 million, a P/E ratio of -1.09 and a beta of 0.48. The business has a fifty day simple moving average of $1.69 and a 200 day simple moving average of $1.57. Ikena Oncology, Inc. has a 12 month low of $1.02 and a 12 month high of $4.66.

Ikena Oncology (NASDAQ:IKNA) last announced its earnings results on Thursday, August 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.04. As a group, sell-side analysts predict that Ikena Oncology, Inc. will post -1.03 EPS for the current fiscal year.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.